MedCity News
NOVEMBER 13, 2022
While telehealth has provided many benefits throughout the pandemic, it can be a lonely and sterile way of receiving treatment. Individuals experiencing substance use disorder who only receive treatment through telehealth may miss opportunities to connect with others in support of the recovery process.
PharmExec
NOVEMBER 13, 2022
Monday, November 14th, 2022 at 7am PST | 10am EST | 3pm GMT | 4pm CET Discover promotion mix optimization approaches to balance and future-fit your investment strategy and maximize the impact of your customer engagement. Harness the power of AI to measure, model, and benchmark channel response.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
NOVEMBER 13, 2022
The United States’ response to addiction and substance use disorders is a criminal justice response and not a public health response — but it shouldn’t be that way, one expert said at Engage at HLTH.
Pharmaceutical Technology
NOVEMBER 13, 2022
The US Food and Drug Administration (FDA) has granted approval for AstraZeneca ’s Imfinzi (durvalumab) plus Imjudo (tremelimumab) and platinum-based chemotherapy to treat Stage IV (metastatic) non-small cell lung cancer (NSCLC) in adults. The approval was based on the findings from the randomised, multicentre, open-label, international Phase III POSEIDON trial.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
MedCity News
NOVEMBER 13, 2022
FDA approval of AstraZeneca’s Imjudo comes less than three weeks after the antibody won its first approval in liver cancer. Both regulatory decisions cover use of the drug in combination with another AstraZeneca immunotherapy, Imfinzi.
MedCity News
NOVEMBER 13, 2022
This year was marked by a marked rise in health tech layoffs, reduced health tech investment and the continued rise of retail health. What does this mean for healthcare investment in 2023?
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
NOVEMBER 13, 2022
The healthcare industry needs a regulated system that can live in between the health information management and release of information departments. It is time for both sides of this network to fully address the need to create a digital pipeline that delivers the request of information and records between two parties.
MedCity News
NOVEMBER 13, 2022
Health plans are in a unique time of change and have the opportunity to be seen as partners for success with employers and providers. Here are a few key healthcare trends that health plans should watch in the coming months.
Expert insights. Personalized for you.
116 
Let's personalize your content